Prevalence and risk factors of clopidogrel non-response among Saudi patients undergoing coronary angiography

References

1. ↵
   1. Patrono C,
   2. Renda G

   (1997) Platelet activation and inhibition in unstable coronary syndromes. Am J Cardiol 80:17E–20E.

   OpenUrlCrossRefPubMed
2. ↵
   (1994) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 308:81–106.

   OpenUrlAbstract/FREE Full Text
3. ↵
   1. Yusuf S,
   2. Zhao F,
   3. Mehta SR,
   4. Chrolavicius S,
   5. Tognoni G,
   6. Fox KK

   (2001) Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without st-segment elevation. N Engl J Med 345:494–502.

   OpenUrlCrossRefPubMedWeb of Science
4. ↵
   1. CAPRIE Steering Committee

   (1996) A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (caprie). Caprie Steering Committee. Lancet 348:1329–1339.

   OpenUrlCrossRefPubMedWeb of Science
5. ↵
   1. Sweeny JM,
   2. Gorog DA,
   3. Fuster V

   (2009) Antiplatelet drug ‘resistance’. Part 1: Mechanisms and clinical measurements. Nat Rev Cardiol 6:273–282.

   OpenUrlCrossRefPubMedWeb of Science
6. ↵
   1. Angiolillo DJ

   (2009) Variability in responsiveness to oral antiplatelet therapy. Am J Cardiol 103(3 Suppl):27A–34A.

   OpenUrlCrossRefPubMedWeb of Science
7. ↵
   1. Jung HJ,
   2. Sir JJ

   (2011) Recurrent myocardial infarction due to one subacute and two very late thrombotic events of drug-eluting stent associated with clopidogrel resistance. J Invasive Cardiol 23:E15–E18.

   OpenUrlPubMed
8. ↵
   1. Campo G,
   2. Fileti L,
   3. de Cesare N,
   4. Meliga E,
   5. Furgieri A,
   6. Russo F,
   7. et al.

   (2010) Long-term clinical outcome based on aspirin and clopidogrel responsiveness status after elective percutaneous coronary intervention: A 3t/2r (tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel) trial substudy. J Am Coll Cardiol 56:1447–1455.

   OpenUrlFREE Full Text
9. ↵
   1. Hochholzer W,
   2. Trenk D,
   3. Bestehorn HP,
   4. Fischer B,
   5. Valina CM,
   6. Ferenc M,
   7. et al.

   (2006) Impact of the degree of peri-interventional platelet inhibition after loading with clopidogrel on early clinical outcome of elective coronary stent placement. J Am Coll Cardiol 48:1742–1750.

   OpenUrlFREE Full Text
10. ↵
    1. Nguyen TA,
    2. Diodati JG,
    3. Pharand C

    (2005) Resistance to clopidogrel: A review of the evidence. J Am Coll Cardiol 45:1157–1164.

    OpenUrlFREE Full Text
11. ↵
    1. Celik T,
    2. Iyisoy A,
    3. Gul H,
    4. Isik E

    (2009) Clopidogrel resistance: A diagnostic challenge. Int J Cardiol 131:267–268.

    OpenUrlPubMed
12. ↵
    1. Harrison P,
    2. Frelinger AL 3rd.,
    3. Furman MI,
    4. Michelson AD

    (2007) Measuring antiplatelet drug effects in the laboratory. Thromb Res 120:323–336.

    OpenUrlCrossRefPubMedWeb of Science
13. ↵
    1. Kim H,
    2. Lee HK,
    3. Han K,
    4. Jeon HK

    (2009) Prevalence and risk factors for aspirin and clopidogrel resistance in patients with coronary artery disease or ischemic cerebrovascular disease. Ann Clin Lab Sci 39:289–294.

    OpenUrlAbstract/FREE Full Text
14. 1. Kar R,
    2. Meena A,
    3. Yadav BK,
    4. Yadav R,
    5. Kar SS,
    6. Saxena R

    (2013) Clopidogrel resistance in north indian patients of coronary artery disease and lack of its association with platelet adp receptors p2y1 and p2y12 gene polymorphisms. Platelets 24:297–302.

    OpenUrlCrossRefPubMedWeb of Science
15. ↵
    1. Angiolillo DJ,
    2. Fernandez-Ortiz A,
    3. Bernardo E,
    4. Ramirez C,
    5. Barrera-Ramirez C,
    6. Sabate M,
    7. et al.

    (2005) Identification of low responders to a 300-mg clopidogrel loading dose in patients undergoing coronary stenting. Thromb Res 115:101–108.

    OpenUrlCrossRefPubMedWeb of Science
16. ↵
    1. Alhabib KF,
    2. Hersi A,
    3. Alfaleh H,
    4. Alnemer K,
    5. Alsaif S,
    6. Taraben A,
    7. et al.

    (2011) Baseline characteristics, management practices, and in-hospital outcomes of patients with acute coronary syndromes: Results of the Saudi project for assessment of coronary events (space) registry. J Saudi Heart Assoc 23:233–239.

    OpenUrlCrossRefPubMed
17. ↵
    1. Godino C,
    2. Mendolicchio L,
    3. Figini F,
    4. Latib A,
    5. Sharp AS,
    6. Cosgrave J,
    7. et al.

    (2009) Comparison of VerifyNow-p2y12 test and flow cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy? Thromb J 7:4.

    OpenUrlCrossRefPubMed
18. ↵
    1. Snoep JD,
    2. Hovens MM,
    3. Eikenboom JC,
    4. van der Bom JG,
    5. Jukema JW,
    6. Huisman MV

    (2007) Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. Am Heart J 154:221–231.

    OpenUrlCrossRefPubMedWeb of Science
19. ↵
    1. Maruyama H,
    2. Takeda H,
    3. Dembo T,
    4. Nagoya H,
    5. Kato Y,
    6. Fukuoka T,
    7. et al.

    (2011) Clopidogrel resistance and the effect of combination cilostazol in patients with ischemic stroke or carotid artery stenting using the VerifyNow p2y12 assay. Intern Med 50:695–698.

    OpenUrlCrossRefPubMed
20. ↵
    1. Cuisset T,
    2. Frere C,
    3. Quilici J,
    4. Morange PE,
    5. Nait-Saidi L,
    6. Carvajal J,
    7. et al.

    (2006) Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non-st-segment elevation acute coronary syndrome undergoing coronary stenting. J Am Coll Cardiol 48:1339–1345.

    OpenUrlFREE Full Text
21. ↵
    1. Hall HM,
    2. Banerjee S,
    3. McGuire DK

    (2011) Variability of clopidogrel response in patients with type 2 diabetes mellitus. Diab Vasc Dis Res 8:245–253.

    OpenUrlCrossRefPubMed
22. ↵
    1. Angiolillo DJ,
    2. Suryadevara S

    (2009) Aspirin and clopidogrel: Efficacy and resistance in diabetes mellitus. Best Pract Res Clin Endocrinol Metab 23:375–388.

    OpenUrlCrossRef
23. ↵
    1. Angiolillo DJ,
    2. Fernández-Ortiz A,
    3. Bernardo E,
    4. Barrera Ramírez C,
    5. Sabaté M,
    6. Fernandez C,
    7. et al.

    (2004) Platelet aggregation according to body mass index in patients undergoing coronary stenting: Should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 16:169–174.

    OpenUrlPubMed
24. ↵
    1. Feher G,
    2. Koltai K,
    3. Alkonyi B,
    4. Papp E,
    5. Keszthelyi Z,
    6. Kesmarky G,
    7. Toth K

    (2007) Clopidogrel resistance: Role of body mass and concomitant medications. Int J Cardiol 120:188–192.

    OpenUrlCrossRefPubMedWeb of Science
25. ↵
    1. Akturk IF,
    2. Caglar FN,
    3. Erturk M,
    4. Tuncer N,
    5. Yalcin AA,
    6. Surgit O,
    7. et al.

    (2014) Hypertension as a risk factor for aspirin and clopidogrel resistance in patients with stable coronary artery disease. Clin Appl Thromb Hemost 20:749–754.

    OpenUrlCrossRefPubMed
26. ↵
    1. Musallam KM,
    2. Charafeddine K,
    3. Bitar A,
    4. Khoury M,
    5. Assaad S,
    6. Beresian J,
    7. et al.

    (2011) Resistance to aspirin and clopidogrel therapy. Int J Lab Hematol 33:1–18.

    OpenUrlPubMed
27. ↵
    1. Qureshi Z,
    2. Hobson AR

    (2013) Clopidogrel “resistance”: Where are we now? Cardiovasc Ther 31:3–11.

    OpenUrlCrossRefPubMed
28. 1. Uchiyama S

    (2011) Clopidogrel resistance: Identifying and overcoming a barrier to effective antiplatelet treatment. Cardiovasc Ther 29:e100–e111.

    OpenUrlPubMed
29. ↵
    1. Patti G,
    2. Nusca A,
    3. Mangiacapra F,
    4. Gatto L,
    5. D’Ambrosio A,
    6. Di Sciascio G

    (2008) Point-of-care measurement of clopidogrel responsiveness predicts clinical outcome in patients undergoing percutaneous coronary intervention results of the armyda-pro (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Platelet Reactivity Predicts Outcome) study. J Am Coll Cardiol 52:1128–1133.

    OpenUrlFREE Full Text
30. ↵
    1. Amsterdam EA,
    2. Wenger NK,
    3. Brindis RG,
    4. Casey DE Jr.,
    5. Ganiats TG,
    6. Holmes DR Jr.,
    7. et al.

    (2014) 2014 AHA/ACC Guideline for the Management of Patients with Non-ST-Elevation Acute Coronary Syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 64:e139–e228.

    OpenUrlFREE Full Text
31. ↵
    1. Gajos G,
    2. Zalewski J,
    3. Nessler J,
    4. Zmudka K,
    5. Undas A,
    6. Piwowarska W

    (2012) Polyunsaturated omega-3 fatty acids improve responsiveness to clopidogrel after percutaneous coronary intervention in patients with cytochrome P450 2C19 loss-of-function polymorphism. Kardiol Pol 70:439–445.

    OpenUrlPubMed